The online version of this article (https://doi.org/10.1007/s00198-018-4604-8) contains supplementary material, which is available to authorized users.
The Forteo Patient Registry (FPR) aims to estimate the incidence of osteosarcoma in US patients treated with teriparatide. Enrollment began in 2009 and will continue through 2019, with linkage planned through 2024. To date, no incident cases of osteosarcoma have been identified among patients registered in the FPR.
The Forteo Patient Registry (FPR) was established in 2009 to estimate the incidence of osteosarcoma in US patients treated with teriparatide. The objective of this paper is to describe study methods, challenges encountered, and progress to date.
The FPR is a prospective US registry designed to link data from participants annually with state cancer registries. Patient enrollment is planned for 10 years (2009–2019) and annual linkage with US state cancer registries for 15 years (2010–2024). All US state cancer registries and DC were invited to participate. Patients are recruited using pre-enrollment materials included in teriparatide device packaging, kits, and brochures distributed by health-care providers; a toll-free number; and a study website. A linkage algorithm is used to match data from enrolled participants with cancer registry data.
For the eighth annual linkage in 2017, information necessary for linkage with 63,270 patients in the FPR was submitted to each of the 42 participating registries. These patients contributed approximately 242,782 person-years of follow-up. A total of 5268 adult osteosarcoma cases diagnosed since January 1, 2009, were available for linkage from participating state cancer registries. To date, no incident cases of osteosarcoma have been identified among patients registered in the FPR.
Based on the estimated 242,782 person-years of observation as of the eighth annual linkage and projecting current enrollment rate to study end in 2024, it is anticipated that the completed study will be able to detect a fourfold increase in the risk of osteosarcoma if one exists.
Dempster DW, Zhou H, Recker RR, Brown JP, Recknor CP, Lewiecki EM, Miller PD, Rao SD, Kendler DL, Lindsay R, Krege JH, Alam J, Taylor KA, Melby TE, Ruff VA (2018) Remodeling- and modeling-based bone formation with teriparatide versus denosumab: a longitudinal analysis from baseline to 3 months in the AVA study. J Bone Miner Res 33:298–306 CrossRefPubMed
CenterWatch (2017) Forteo (teriparatide). http://www.centerwatch.com/drug-information/fda-approved-drugs/drug/812/forteo-teriparatide. Accessed 28 Sept 2017
von Schéele B, Martin RD, Gilsenan AW, Ceberg J, Andrews EB, Masica D et al (2009) The European postmarketing adult osteosarcoma surveillance study characteristics of patients: a preliminary report. Acta Orthop 80(suppl 334):67–74
European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) (2017) Forteo/Forsteo post-approval osteosarcoma surveillance study: EU PAS Register No. EUPAS8540. http://www.encepp.eu/encepp/viewResource.htm;jsessionid?id=8541. Accessed 12 Oct 2017
Food and Drug Administration (2009) Approval letter: Forteo (teriparatide, rPTH[1-34]) for the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021318s012ltr.pdf. Accessed 28 Sept 2017
Surveillance, Epidemiology, and End Results (SEER) Program ( www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2016 Sub (2000-2014) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969–2015 Counties, National Cancer Institute, DCCPS, Surveillance Research Program. Released April 2017, based on the November 2016 submission
Surveillance, Epidemiology, and End Results (SEER) Program ( www.seer.cancer.gov) SEER*Sta t Database: Incidence - SEER 17 Regs Public-Use, Nov 2005 Sub (2000-2003), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. Released April 2006, based on the November 2005 submission
Harris DH, Midkiff K, Gilsenan A, Andrews E (2010) Public health surveillance collaboration: establishing a linkage algorithm with cancer registries for the Forteo Patient Registry. Poster presented at the North American Association of Central Cancer Registries Annual Conference; June 2010. Quebec City, Quebec, Canada
IMS Health. Prescription data (LRx). January 2009-June 2017. Data provided October 2017
Kellier-Steele N, Gilsenan A, Midkiff K, Harris D, Andrews E (2016) Complementary observational studies assessing the incidence of a rare cancer outcome by linking state cancer registry data to large pharmacy claims databases in the United States. Pharmacoepidemiol Drug Saf 25:152
Fraser G, Deapen, D, Burton B, Bennett H (2010) The variety of experience in working with 35 U.S. cancer registries: matching Adventist Health Study-2 and registry data. Presented at the North American Association of Central Cancer Registries Annual Conference; June 2010. Quebec City, Quebec, Canada
- The Forteo Patient Registry linkage to multiple state cancer registries: study design and results from the first 8 years
- Springer London
Neu im Fachgebiet Orthopädie und Unfallchirurgie
e.Med Kampagnen-Visual, Mail Icon II